CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.64M, lower than 95% of all stocks globally
- PositionPrice-to-book is 16.73×, higher than 95% of its Biotechnology peers (median 2.86×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.54BEUR8.64B · vs all stocks (USD)
Revenue (TTM)
4.92MEUR5.64M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2480xvs all stocks
52-Week Change
20.84%vs all stocks
Market Capitalization
7.54BEUR8.64B · vs all stocks (USD)
Enterprise Value
6.73BEUR7.71B · vs all stocks (USD)
Forward P/E
-30.57xvs Biotechnology peers
Price to Book (MRQ)
16.73xvs Biotechnology peers
Enterprise to Revenue
1.37Kxvs Biotechnology peers
Enterprise to EBITDA
-26.50xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4183.70%vs Biotechnology peers
Return on Assets (TTM)
-44.65%vs Biotechnology peers
Return on Equity (TTM)
-157.07%vs Biotechnology peers
Revenue (TTM)
4.92MEUR5.64M · vs all stocks (USD)
Revenue per Share (TTM)
0.0670EURUpdated Sep 23, 2026Quarterly Revenue Growth
35.20%vs Biotechnology peers
Gross Profit (TTM)
4.92MEUR5.64M · vs all stocks (USD)
EBITDA (TTM)
-254.00MEUR-291.03M · vs all stocks (USD)
Net Income (TTM)
-332.20MEUR-380.62M · vs all stocks (USD)
Operating Cash Flow (TTM)
-178.37MEUR-204.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-114.47MEUR-131.16M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Operating Income
-246.06MEUR-281.92M · vs all stocks (USD)
Pre-tax Income
-330.25MEURFY2025 · Dec 31, 2025Income Tax Expense
5.85MEURFY2025 · Dec 31, 2025Net Income
-336.10MEURFY2025 · Dec 31, 2025EBIT
-301.77MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-268.99MEURFY2025 · Dec 31, 2025Research & Development
177.76MEURFY2025 · Dec 31, 2025Selling, General & Administrative
72.86MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.57MEURFY2025 · Dec 31, 2025Non-operating Interest Income
5.75MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
28.48MEURFY2025 · Dec 31, 2025EPS (Basic)
-4.83EURFY2025 · Dec 31, 2025EPS (Diluted)
-4.83EURFY2025 · Dec 31, 2025Basic Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-336.10MEURFY2025 · Dec 31, 2025Operating Cash Flow
-270.21MEURFY2025 · Dec 31, 2025Free Cash Flow
-270.35MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
516.68MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-336.10MEURFY2025 · Dec 31, 2025Depreciation & Amortization
1.07MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.85MEURFY2025 · Dec 31, 2025Stock-based Compensation
35.40MEURFY2025 · Dec 31, 2025Other Non-cash Items
22.03MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
7.04MEURFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.21MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
710.00KEURFY2025 · Dec 31, 2025Capital Expenditures
-142.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00EURFY2025 · Dec 31, 2025Other Investing Activity
-13.58MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.72MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
-59.53MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
-40.61MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
547.98MEURFY2025 · Dec 31, 2025Shares Outstanding
79.29MSharesUpdated Sep 23, 2026Float Shares
68.57MSharesUpdated Sep 23, 2026% Held by Insiders
4.18%vs all stocks
% Held by Institutions
47.59%vs all stocks
Total Cash (MRQ)
491.55MEUR563.20M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.20EURUpdated Sep 23, 2026Total Debt (MRQ)
34.21MEUR39.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0796xvs Biotechnology peers
Current Ratio (MRQ)
8.25xvs Biotechnology peers
Book Value per Share (MRQ)
5.42EURUpdated Sep 23, 2026Total Assets
584.34MEUR669.51M · vs all stocks (USD)
Total Current Assets
551.24MEURFY2025 · Dec 31, 2025Total Liabilities
129.14MEURFY2025 · Dec 31, 2025Total Non-current Assets
33.10MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
66.11MEURFY2025 · Dec 31, 2025Total Current Liabilities
63.02MEURFY2025 · Dec 31, 2025Cash
38.14MEURFY2025 · Dec 31, 2025Cash Equivalents
478.54MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
516.68MEURFY2025 · Dec 31, 2025Other Short-term Investments
13.70MEURFY2025 · Dec 31, 2025Accounts Payable
37.55MEURFY2025 · Dec 31, 2025Short-term Debt
1.30MEURFY2025 · Dec 31, 2025Deferred Revenue
0.00EURFY2025 · Dec 31, 2025Long-term Debt
554.00KEURFY2025 · Dec 31, 2025Other Non-current Liabilities
30.24MEURFY2025 · Dec 31, 2025Common Stock (Book)
785.00KEURFY2025 · Dec 31, 2025Retained Earnings
-738.48MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
455.20MEUR521.56M · vs all stocks (USD)
52-Week Low
60.45EURUpdated Sep 23, 202652-Week High
139.00EURUpdated Sep 23, 202652-Week Change
20.84%vs all stocks
Beta
-0.2480xvs all stocks
50-Day MA
105.64EURUpdated Sep 23, 2026200-Day MA
102.94EURUpdated Sep 23, 2026Avg 10-Day Volume
131.18KSharesUpdated Sep 23, 2026Avg 30-Day Volume
140.59KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-4.61EURUpdated Sep 23, 2026Other Income / Expense
-31.71MEURFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 16.73×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 16.73Industry median: 2.86Industry P95: 13.08Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.64M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,637,139.2Global P5: 33,357,653.812
Market cap is $8.64B, above the global median of $1.18BNotable
Market cap (USD): 8,637,573,062.026Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Triveni Engineering & Industries Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Kangxin New Materials Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hyosung Heavy Industries Corporation
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated